Tailoring the length of antiviral treatment for hepatitis C

Gut

Volumn 59, Issue 1, 2010, Pages 1-5

  Mangia, Alessandra ^a   Andriulli, Angelo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; BODY MASS; CHRONIC HEPATITIS; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; PARAMETER; PRIORITY JOURNAL; RELAPSE; REVIEW; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; VIRUS STRAIN;

ALGORITHMS; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 73449089106     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.179606     Document Type: Review

References (37)

1. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000;182:28-35.
2. Perelson AS, Hermann E, Micol F, et al. New kinetic models for hepatitis C virus. Hepatology 2005;42:749-54.
3. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-956.
4. Fried MW, Schiffman ML, Reddy KR, et al. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
5. Hadziyannis SJ, Sete H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
6. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001;358:1241-2.
7. Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al. International multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatology 2005;43:250-7.
8. Ferenci P, Fried M, Shiffman M, et al. Predicting sustained responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005;43:425-33.
9. Davis GL, WongJB, McHutchison J, et al. Early virologic response to treatment with peginterferon alfa-2 plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;3:645-52.
10. Mangia A, Antonucci F, Brunetto M, et al. The use of molecular assays in the management of viral hepatitis. Dig Liver Dis 2008;20:396-404.
11. Pordard F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46:76-84.
12. Marcellin P, Heatchote EJ, Craxì A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the accordion regimen? J Hepatol 2007;47:580-7.
13. Mangia A, Minerva N, Bacca, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50.
14. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia. J Hepatol 2006;44:97-103.
15. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha 2a ribavirin therapy. Hepatology 2006;43:954-60.
16. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1b infected chronic hepatitis C patients: a randomised trial. Hepatology 2008;47:1884- 93.
17. Liu CH, Liu CJ, Liang CC, et al. Pegylated interferon α2a plus ribavirin for treatment naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomised controlled trial. Clin Infect Dis 2008;47:1260-69.
18. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-8.
19. Berg Th, Teuber G, Klinder H, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50:369-77.
20. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for weeks a pilot study. Hepatology 2004;40:1260-5.
21. Mangia A, Santoro R, Minerva N, et al. PegInterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
22. Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha 2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
23. Dalgard O, Bjoøro K, Ring-Larsen H, et al. A randomized controlled trial of pegylated interferon alfa and ribavirin for 14 vs 24 weeks in patients with HCV genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42.
24. Yu ML, Day CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16-versus 24-weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-9.
25. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34.
26. Andriulli A, Dalgard O, Bjoro K, et al. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liver Dis 2006;38:741-8.
27. Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009;49:358-63.
28. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long term response among patient infected with genotype 1 hepatitis virus. J Infect Dis 2004;189:964-70.
29. Buti M, Valdes A, Sanchez-Avila F, et al. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 2003;37:1236-7.
30. Berg T, Von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of PegInterferon alfa 2a plus ribavirin. Gastroenterology 2006;130:1086-97.
31. Sanchéz-Tapias J, Diago M, Escartin P, et al. Peginterferon alfa 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60.
32. Perlman BI, Ehleben C, Saifee S, et al. Treatment extension to 72 weeks of pegintereron and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-94.
33. Buti M, Lurie Y, Zakharova NG, et al Extended treatment duration in chronic hepatitis C genotype-1 infected slow responders: final results of the SUCCESS Study. J Hepatol 2009;50:S55.
34. Ide T, Hino T, Ogata K, et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009;104:70-5.
35. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha 2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837- 45.
36. Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virologic response. J Hepatol 2007;46(suppl. 1):S6.
37. Shiffman ML, Minola E, Barange K, et al. Characterisation of HCV genotype 2/3 patients without a rapid virological response (RVR) optimising treatment by predicting slower responders to peginterferon α2a plus ribavirin. J Hepatol 2007;46(suppl 1):S24